fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ipratropium bromide/salbutamol

All products: Limited Use (codes 256, 257, 258, 259)

Teva-Combo Sterinebs · DIN 02272695 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Combo Sterinebs · DIN 02272695 Manufacturer: Teva Canada Limited; listing date 2006-01-24 Health Canada: Marketed since 2012-07-17 · brand TEVA-COMBO STERINEBS · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Combo Sterinebs: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.

Ministry pays: $0.8066 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02272695)

Source record
DIN 02272695: Teva-Combo Sterinebs Raw flags: sec12=Y, sec3=Y Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id TEV Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8066; ministry $0.8066 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272695 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75820
Interchangeable products
Combivent UDV · DIN 02231675 · not recorded Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Shortage status: resolved shortage (ended April 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02272695
Shortage record checked October 6, 2026

Other products in the same Health Canada class (R03AL): coverage varies; not interchangeable

  • Olodaterol + tiotropium (Inspiolto Respimat): limited Use 459
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation Solution in unit dose vials is indicated for the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD) who require regular treatment with both ipratropium and salbutamol. Treatment should be initiated and administered under medical supervision, e.g. in the hospital setting. Home based treatment can be recommended in exceptional cases (severe symptoms or experienced patients requiring higher doses) when a low dose rapid acting beta-agonist bronchodilator has been insufficient in providing relief after consultation with an experienced physician. Administration should be stopped when sufficient symptom relief is achieved. Pediatrics: The efficacy and safety in children and adolescents under 18 years has not been established. TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation Solution is not indicated in this patient population. Geriatrics: Page 3 of 48 Elderly patients can use TEVA-COMBO Sterinebs® (s… https://pdf.hres.ca/dpd_pm/00033894.PDF PM date: March 1, 2016 Source product: TEVA-COMBO STERINEBS; DIN 02272695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.